Instead of or in addition to disclosure through the Open Payments Program, imagine that the law also requires physicians/PIs to disclose their receipt of compensation from an applicable manufacturer to their patients or potential research subjects during the informed consent process. Do you believe that such a law will ensure that patients and research subjects are better informed about whether to pursue the recommended treatment or clinical trial? Why or why not?